Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors

21 Mar 2019

Abstract excerpt

Abstract Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with recurrent loss-of-function alterations in polycomb-repressive complex 2 (PRC2), a histone-modifying complex involved in transcriptional silencing. To understand the role of PRC2 loss in pathogenesis and identify therapeutic targets, we conducted parallel global epigenomic and proteomic analysis of archival formalin-fixed,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Neuroblastoma Research and Treatments
Share to Neurofibromatosis and Schwannoma Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30898839
DOI: 10.1158/0008-5472.can-18-3704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath TumorsPMID 30898839Read ↗

The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.Semantic proximity Read ↗

Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNASemantic proximity Read ↗

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.Semantic proximity Read ↗

Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNASemantic proximity Read ↗

Integrated Proteomic and Epigenomic Analysis Reveals IGF2 as a Vulnerability in PRC2-Deficient Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumorSemantic proximity Read ↗

The Cell Surface Proteome of Malignant Peripheral Nerve Sheath Tumors Reveals Therapeutic TargetsSemantic proximity Read ↗

Identification of Malignant Peripheral Nerve Sheath Tumor subtypes with distinct genomic identitiesSemantic proximity Read ↗

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.Semantic proximity Read ↗

H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumoursSemantic proximity Read ↗

A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for TreatmentSemantic proximity Read ↗

PRC2 Inactivating Mutations in Cancer are Synthetic Lethal with DNMT1 Targeted Therapy via Enhanced Viral MimicrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.